Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | ESRRG | P62508 | 4/20 | 0.36 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579938 | 0.86 | MAPT (0.42) | NR1H4ESRRGESRRBTP53MAPT | |
| SCHEMBL3578978 | 0.85 | CNR1 (0.43) | NR1H4ESRRGESRRBMEN1CYP1A2 | |
| SCHEMBL3579634 | 0.84 | SERPINE1 (0.40) | NR1H4ESRRGESRRBSIGMAR1TP53 | |
| SCHEMBL3581360 | 0.83 | MCL1 (0.40) | MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL3583634 | 0.82 | SERPINE1 (0.39) | NR1H4ESRRGESRRBTP53MAPT | |
| SCHEMBL3586388 | 0.81 | ESRRG (0.38) | NR1H4ESRRGESRRBSIGMAR1TP53 | |
| SCHEMBL3583628 | 0.81 | MCL1 (0.40) | MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL3575452 | 0.81 | KMT2A (0.42) | NR1H4ESRRGESRRBSIGMAR1MEN1 | |
| SCHEMBL3570707 | 0.80 | C5AR1 (0.39) | NR1H4ESRRGESRRBTP53MAPT | |
| SCHEMBL3581545 | 0.80 | CNR1 (0.40) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | NR1H4 2668/4885ESRRG 4686/4885ESRRB 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.